Articles On Recce Pharmaceuticals (ASX:RCE)

Shares in Perth-founded Recce Pharmaceuticals have lifted after the company announced it had received a grant intent from the Australian Patent Office for an anti-virus agent.

The share market retreated for the first time in five sessions after Wall Street’s winning start to 2023 lost momentum. The S&P/ASX 200 declined 14 points or 0.19 per cent by mid-session. A loss today would be only the second in six...

Recce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synthetic anti-infectives The grant from the Australian Patent Office relates to the RECCE 327 (R327) and RECCE 529 (R529) formulations, mar...

Recce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synthetic anti-infectives The grant from the Australian Patent Office relates to the RECCE 327 (R327) and RECCE 529 (R529) formulations, mar...

MGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAlta gets second patent in Japan   MGC Pharma on track for FDA submission MGC Pharma (ASX:MXC) has completed the full pre-clinical rodents st...

It can take a long time to bring a new drug to market, but companies that succeed reap mighty rewards. Any time a company is working in drug manufacturing and clinical research, the compound needs to be tested on human subjects to ensure...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

What a day it’s been, what a magic day… and other children’s song lyrics that probably won’t make much sense to anyone who has never been subjected to the unrelenting horrors of Jimmy Giggle and his clearly drug-addled owl. Anyhow – since i...

Recce Pharmaceuticals (RCE) establishes a new anti-infective research unit within the Murdoch Children’s Research Institute’s facilities in MelbourneThe company has secured a dedicated Murdoch Children’s research team of infectious disease...

Recce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phase I/II clinical trialThe trial will assess one of Recce’s leading drug candidates, R327, as a spray-on antibiotic therapy to treat mild skin...

HITIQ signs with UK rugby league  Recce receives ethics approval to commence Phase 1/2 trial Healius appoints new CEO   HITIQ Limited (ASX: HIQ) rose 8% this morning after announcing a two-year commercial agreement with UK’s Rugby Footbal...

ASX 200 down 0.55% on lower than normal volume  Small cap index falls 0.96% and 10 out 11 sectors finish lower Economy grows for the fourth consecutive quarter, up 0.6%    The ASX200 was down 0.55% today, and the ASX Emerging Companies...

Recce Pharmaceuticals (RCE) has multiple trials in the pipeline following the September quarterRCE reported no serious adverse effects in the seventh cohort who were dosed with 6000mg of its R327 drug and the positive outcomes will see a ph...

It’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own small portions of much larger things, you owe it to yourself to sit back and relax in front of a warm, crackling fire. So crack open a bott...

Recce Pharmaceuticals (RCE) reports that independent studies of its RECCE 327 (R327) product found the drug to significantly reduce SARS-CoV-2 in Syrian golden hamstersThe company says the study results provide it with proof of concept that...

Highlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points. Over the last five days, the index has lost 4.56% and has shed 12.03% over the last 52 weeks. Materials was the best performing sector,...

Recce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next yearThe company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this...

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

Reece Pharmaceuticals (RCE) will deliver the opening research and development address at the World Anti-Microbial Resistance (AMR) CongressThe Congress will take place today and tomorrow and is the world’s largest AMR conference with over 1...

Recce Pharmaceuticals (ASX:RCE) has announced the appointment of Dr John Prendergast as its executive chairman.

Highlights The ASX 200 benchmark index closed up today (5 September), gaining 0.34% to end at 6,852.20 points. Over the last five days, the index has lost 1.63% and it has plunged 8.92% over the last 52 weeks. Energy was the best perf...

Recce Pharmaceuticals (RCE) appoints Dr John Prendergast as Executive Chairman, effective immediatelyDr Prendergast has experience in commercialising pharmaceuticals for global markets, most notably the US, and has a background in microbiol...

Imaging specialist Clarity opens patient recruitment in Australia and will start Phase 2 trial soon Another imaging specialist Optiscan has made a FDA Pre-Market Notification 510(k) submission  Recce Pharma says dosing of Cohort 7 of its P...

Recce Pharmaceuticals (RCE) reports no serious adverse effects from intravenously dosing the seventh cohort of its phase one clinical trial with 6000 milligrams of its R327 drug As part of the trial, 10 healthy male subjects were dosed for...

The ASX is poised to open lower on Monday Wall Street ends a four-week winning streak last week Oil and gold also edge lower Local shares are set to open lower today. At 8am AEST, the ASX 200 September futures contract is pointing down by...

Recce Pharmaceuticals (RCE) progresses clinical trials of its R327 drug candidate during the June quarter One of the company’s standout moments for the period has been successfully dosing two cohorts with higher doses in its phase one intr...

Emerging Australian company Recce Pharmaceuticals (ASX:RCE) has appointed an experienced industry executive to lead the translation of its pipeline of anti-infectives.

Recce Pharmaceuticals (RCE) appoints Dr Philip Sutton as Vice President of Translational Sciences This role will take responsibility for advancing the company’s compounds across a portfolio of infectious disease programs with unmet medical...

A number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broader market today. The benchmark S&P/ASX 200 Index (ASX: XJO) backtracked yet again, ending Thursday’s session 1.97% lower at 6,568.1 poin...

Recce Pharmaceuticals jumps on positive safety data during trial dosing participants with anti-infective · Fenix Resources moves to full ownership ...

ShareCafeEvening Report: 21 June, 2022 by Melissa Darmawan   Australian shares snapped a seven-day losing streak led by resource and financial stocks amid the US futures pointing to a rise as Wall Street looks to resume trade after a long w...

Recce Pharmaceuticals (RCE) reports positive safety data in ten male subjects who received 4000mg of Recce’s R327 product as part of a first-phase clinical trial The subjects are part of the sixth cohort to be intravenously dosed with R327...

ShareCafeLunch Report: 21 June, 2022 by Melissa Darmawan   The Australian sharemarket is set to snap a seven-day losing streak as investors were relieved that RBA governor Philip Lowe doesn’t see a local recession coming. At noon, the S&amp...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is rebounding after hitting a near multi-year low of 56 cents yesterday. This comes after the pharmaceutical company provided an update on its development of a new class of synthetic a...

21 Jun 2022 - A snapshot of the stocks on the move, featuring ResApp (ASX:RAP), Radiopharm Theranostics (ASX:RAD), and Reece Pharmaceuticals (ASX:RCE).

ResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase 1 trial Proteomics secures exclusive biomakers license Smartphone-based respiratory diagnostic maker, ResApp Health (ASX:RAP), plunged by...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

Recce Pharmaceuticals (RCE) sees its clinical trial receive a good safety profile among ten healthy male subjects The company reported its drug, R327, demonstrated a good tolerability profile among ten male subjects who were intravenously...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Recce Pharmaceuticals (RCE) is set to administer its “high dose” cohort following its successful phase one clinical trial of R327 in the “low dose” cohort The 10 healthy human subjects administered with R327 in the “low dose” cohort showed...

Chimeric wants to accelerate its clinical trial readiness via a deal with WuXi Recce advances to higher dosing in Phase I clinical trial Proteomics engages experts to advance commercialisation Chimeric signs deal with WuXi Cell therapy sp...

Australia-based drug developer Recce Pharmaceuticals (RCE) granted a patent in Hong Kong for two of its synthetic polymer anti-infective drug candidates The patent is called the “Anti-Virus Agent and Method for Treatment of Viral Infection...

ResApp gets takeover offer from Pfizer Recce gets Hong Kong patent RhinoMed comes out of trading halt and rallied 20% Smartphone-based health company ResApp Health (ASX:RAP) surprised the market this morning after revealing that global gi...

Recce Pharmaceuticals (RCE) reports positive safety results from the fourth patient cohort in a first-phase trial of its RECCE 327 (R327) synthetic anti-infective The drug developer dosed 10 healthy male subjects with 1000mg of R327 as par...

Highlights Recce Pharmaceuticals’ R327 exhibits a safe and tolerable profile. The safety profile of R327 at a twenty-fold increase of the initial dosing level is crucial for synergies across the company’s wider-infectious disease portf...

The Tempest, a tale of love, revenge and family set at sea, is thought to be the last play that William Shakespeare wrote alone. One area it doesn’t touch on in detail is staggering riches; a theme now more relevant to shareholders in Tempe...

Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

ASX-listed Recce Pharmaceuticals (RCE) has developed a synthetic anti-infective designed to not only kill bacteria and emerging viral pathogens but treat sepsis before it can take hold Sepsis is the leading cause of hospitalisation in the...

Recce Pharmaceuticals’ (RCE) new class of synthetic anti-infectives drug, the RECCE 327 (R327) has been given the go-ahead for the next set of doses by an Independent Safety Committee (ISC) following a successful Phase I intravenous (IV) c...

Highlights The ASX 200 was trading 0.31% up at 7,113.8 in the first 15 minutes of trading. Brent crude oil rallied sharply to over US$139 per barrel mark on Monday. The energy index was the top gainer, surging 4.69% in early trade....